REPLICor to Present Updated Clinical Trial Data with Combination Treatment Using its HBsAg-release Inhibitors in Patients with Chronic Hepatitis B Infection at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)

Replicor Inc [Pressemappe]
Montreal (ots/PRNewswire) – Updated clinical trial data from REPLICor’s three Asian trials using its nucleic acid polymer (NAP) HBsAg-release inhibitors REP 2055 (REP 9AC) and REP 2139 (REP 9AC’) will be presented at the 10th Annual Meeting of the … Lesen Sie hier weiter…

Ähnliche Beiträge:

  • Positive Phase 2 Clinical Data With Tivantinib in…
  • Eisai Oncology to Present New Research on Product Portfolio…
  • Ibrutinib Three Year Follow-up of Single-Agent and…
  • Ibrutinib RESONATE(TM) Data Show Significant Improvements in
  • Sanofi to Present New Clinical Data at American Diabetes…

Leave a reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>